Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $51.0 million.
- Teva Pharmaceutical Industries' Share-based Compensation rose 5000.0% to $51.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $157.0 million, marking a year-over-year increase of 2764.23%. This contributed to the annual value of $157.0 million for FY2025, which is 2764.23% up from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Share-based Compensation of $51.0 million as of Q4 2025, which was up 5000.0% from $34.0 million recorded in Q3 2025.
- Teva Pharmaceutical Industries' Share-based Compensation's 5-year high stood at $51.0 million during Q4 2025, with a 5-year trough of $24.0 million in Q1 2022.
- Its 5-year average for Share-based Compensation is $32.2 million, with a median of $31.5 million in 2021.
- Per our database at Business Quant, Teva Pharmaceutical Industries' Share-based Compensation crashed by 2307.69% in 2023 and then skyrocketed by 5000.0% in 2025.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Share-based Compensation stood at $33.0 million in 2021, then rose by 9.09% to $36.0 million in 2022, then decreased by 22.22% to $28.0 million in 2023, then rose by 21.43% to $34.0 million in 2024, then skyrocketed by 50.0% to $51.0 million in 2025.
- Its Share-based Compensation stands at $51.0 million for Q4 2025, versus $34.0 million for Q3 2025 and $38.0 million for Q2 2025.